Phase I study of concurrent selective lymph node late course accelerated hyper-fractionated radiotherapy and Capecitabine, Cisplatin for locally advanced esophageal squamous cell carcinoma

Abstract Twelve patients with locally advanced esophageal squamous cell carcinoma were enrolled to evaluate the safety and efficacy of concurrent chemo-radiotherapy. Dose-limiting toxicity was mainly observed at Capecitabine 1500 mg. The maximum-tolerated dose/recommended dose of Capecitabine was 10...

Full description

Saved in:
Bibliographic Details
Published in:Radiotherapy and oncology 2009-12, Vol.93 (3), p.458-461
Main Authors: Li, Bao-sheng, Zhou, Tao, Wang, Zhong-tang, Li, Hong-sheng, Sun, Hong-fu, Zhang, Zhi-cheng, Lin, Hai-qun, Wei, Yu-mei, Gong, He-yi, Huang, Wei, Yi, Yan, Wang, Li-ying
Format: Article
Language:English
Subjects:
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Capecitabine
Carcinoma, Squamous Cell - drug therapy
Carcinoma, Squamous Cell - mortality
Carcinoma, Squamous Cell - radiotherapy
Chemo-radiotherapy
Cisplatin
Cisplatin - administration & dosage
Combined Modality Therapy
Deoxycytidine - administration & dosage
Deoxycytidine - analogs & derivatives
Dose Fractionation, Radiation
Esophageal cancer
Esophageal Neoplasms - drug therapy
Esophageal Neoplasms - mortality
Esophageal Neoplasms - radiotherapy
Female
Fluorouracil - administration & dosage
Fluorouracil - analogs & derivatives
Hematology, Oncology and Palliative Medicine
Humans
Lymphatic Irradiation
Lymphatic Metastasis
Male
Middle Aged
Radiation Injuries
Radiotherapy Dosage
Radiotherapy, Intensity-Modulated
Selective lymph node late course accelerated hyper-fractionated radiotherapy
Survival Rate
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Twelve patients with locally advanced esophageal squamous cell carcinoma were enrolled to evaluate the safety and efficacy of concurrent chemo-radiotherapy. Dose-limiting toxicity was mainly observed at Capecitabine 1500 mg. The maximum-tolerated dose/recommended dose of Capecitabine was 1000 mg. The Kaplan–Meier estimated overall l-year survival rate was 100%.
ISSN:0167-8140
1879-0887
DOI:10.1016/j.radonc.2009.08.002